MolRecordA running record of peptide research, regulation and industry. Cited and dated. Updated weekly.https://molrecord.example/en-gbBPC-157: what the human record containshttps://molrecord.example/entries/bpc-157-human-evidence-2026/https://molrecord.example/entries/bpc-157-human-evidence-2026/As of October 2026 there is no published randomised controlled trial of BPC-157 in humans. Published human data are small pilot studies; a 2015 Phase I never reported; a Phase 2 hamstring-strain trial was registered in February 2026.Mon, 05 Oct 2026 00:00:00 GMTEVIDENCEWho makes peptides: capacity and ownership moveshttps://molrecord.example/entries/peptide-manufacturing-moves-2026/https://molrecord.example/entries/peptide-manufacturing-moves-2026/Samsung Peptide AG published a tender-offer prospectus for PolyPeptide Group on 31 August 2026, with an extraordinary general meeting set for 26 October. Neuland Laboratories is commissioning commercial peptide capacity in India in 2026.Mon, 05 Oct 2026 00:00:00 GMTINDUSTRYA public-health school explains the peptides in the feedhttps://molrecord.example/entries/harvard-chan-peptides-explainer/https://molrecord.example/entries/harvard-chan-peptides-explainer/A 1 October 2026 Q&A from the Harvard T.H. Chan School of Public Health lists BPC-157, TB-500, MOTS-c, CJC-1295 and ipamorelin among synthetic peptides promoted online for recovery and performance.Mon, 05 Oct 2026 00:00:00 GMTPUBLICThe gray market and the state patchworkhttps://molrecord.example/entries/gray-market-state-patchwork/https://molrecord.example/entries/gray-market-state-patchwork/An AJMC feature describes the July advisory vote passing over the objection of FDA staff scientists, states diverging on peptide compounding, and more than forty state attorneys general writing to the agency.Mon, 05 Oct 2026 00:00:00 GMTPOLICYGLP-1 drugs recruit hunger neurons to sustain fat loss, Yale study findshttps://molrecord.example/entries/yale-agrp-neurons-glp1/https://molrecord.example/entries/yale-agrp-neurons-glp1/Researchers at Yale report that GLP-1 therapies recruit agouti-related peptide neurons, long treated as drivers of hunger, to help maintain fat loss.Mon, 05 Oct 2026 00:00:00 GMTPAPERSix peptides recommended for the 503A bulks listhttps://molrecord.example/entries/pcac-recommends-six-peptides/https://molrecord.example/entries/pcac-recommends-six-peptides/On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax for the 503A bulks list. Emideltide was not recommended.Mon, 05 Oct 2026 00:00:00 GMTREGULATIONRetatrutide: four Phase 3 readouts in 2026https://molrecord.example/entries/retatrutide-phase-3-readouts-2026/https://molrecord.example/entries/retatrutide-phase-3-readouts-2026/Between March and July 2026 Eli Lilly reported topline results from TRANSCEND-T2D-1, TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3. Weight reduction at 80 weeks on the 12 mg dose ranged from 20.8 % to 28.3 % depending on the population.Mon, 05 Oct 2026 00:00:00 GMTTRIALWhat GLP-1 users do differently: activity, bone and persistencehttps://molrecord.example/entries/glp1-users-activity-bone-persistence/https://molrecord.example/entries/glp1-users-activity-bone-persistence/Reports in 2026 describe falling physical activity among people on GLP-1 drugs, claims-data signals on bone and joint conditions with long-term use, and one-year persistence nearly doubling since 2021.Mon, 05 Oct 2026 00:00:00 GMTPAPERA peptide–drug conjugate that hits five targets, in micehttps://molrecord.example/entries/quintuple-agonist-peptide-conjugate/https://molrecord.example/entries/quintuple-agonist-peptide-conjugate/A Nature paper describes linking the pan-PPAR agonist lanifibranor to a GLP-1/GIP peptide with a pH-sensitive linker. In mice the conjugate acted on five receptors and produced marked weight reduction.Mon, 05 Oct 2026 00:00:00 GMTPAPERFDA proposes to end 503B compounding of semaglutide, tirzepatide and liraglutidehttps://molrecord.example/entries/fda-proposes-503b-exclusion-glp1/https://molrecord.example/entries/fda-proposes-503b-exclusion-glp1/A 30 April 2026 proposal would exclude the three GLP-1 drugs from the 503B bulks list, closing the outsourcing-facility route that opened during the shortage years.Mon, 05 Oct 2026 00:00:00 GMTREGULATIONOrforglipron approved; the oral GLP-1 questionhttps://molrecord.example/entries/oral-glp1-orforglipron-approval/https://molrecord.example/entries/oral-glp1-orforglipron-approval/April 2026 brought approval of orforglipron, the first oral small-molecule GLP-1 receptor agonist. Oral options so far produce less weight reduction than leading injectables but are easier to make and take.Mon, 05 Oct 2026 00:00:00 GMTTRIALFrom Category 2 to review: how twelve peptides came off the restricted listhttps://molrecord.example/entries/category-2-timeline-2023-2026/https://molrecord.example/entries/category-2-timeline-2023-2026/In September 2023 the FDA placed nineteen peptides in Category 2. In April 2026 it removed twelve of them after their nominations were withdrawn and scheduled advisory meetings to consider adding them to the 503A bulks list.Mon, 05 Oct 2026 00:00:00 GMTREGULATION